drugset / Trial / NCT02787369
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Phase 1
Active not recruiting
3 enrolled
Dana-Farber Cancer Institute
Acetylon Pharmaceuticals Incorporated · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Timeline
- Start
- 2016-05
- Primary completion
- 2026-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | — | Oral |
| Subject | Idelalisib | Small molecule | — | Oral |
| Subject | Ricolinostat | Small molecule | — | Oral |